The nanoemulsion market is expected to register a CAGR of nearly 7.2% during the forecast period of 2021-2026.
The COVID-19 outbreak is expected to have a positive effect on the market for nanoemulsions. Nanoemulsions are used extensively as vaccine carriers and adjuvants. In vaccine development, nanoemulsions are used as they offer various advantages like increasing the surface area of an antigen allowing for favorable antigen presentation, slow release of the antigen, and uniform dispersion, and good stability of the vaccine. In a research article appearing in the September 2020 issue of News-Medical.Net, researchers stated that a potential COVID-19 vaccine can include a cationic nanoemulsion-based system. These nanoemulsion systems can produce immune responses that are similar to live attenuated vaccines but do not run the risk of reversion. These developments are likely to affect the market in a positive manner.
The studied market growth can largely be attributed to factors, such as the increasing burden of chronic diseases and development of vaccines, rising adoption of targeted therapeutics and image-guided therapies and the high stability and chemical properties for efficient drug delivery.
Vaccines play a significant role in the treatment of several chronic and infectious diseases, which gained more prevalence in recent decades. An increasing number of biopharmaceutical companies are using nanoemulsion formulations in the development of vaccines. In June 2019, BlueWillow Biologics, Inc., a nanotechnology based vaccine manufacturer, announced that it had received a United States patent for an intranasal NanoVax anthrax vaccine. The NanoVax nanoemulsion platform could elicit both a systemic and mucosal response when administered intranasally. This was in contrast with other conventional vaccines are injected (intramuscular) and fail to provide mucosal immunity. The NanoVax platform has also been used to develop vaccines against two strains of genital herpes virus HSV1 and HSV2.
The last decade showed several promises, with successful results of nanoemulsion being used as adjuvants for vaccines to treat chronic infections and cancer diseases through targeted therapies. Increasing research projects through institutes, in collaboration with various government funds and companies, are being witnessed, which primarily deal with the improvement of the oral delivery of drugs for the management of chronic diseases. Nanoemulsion provides enhanced transdermal permeation of drugs, which, in turn, increases the plasma concentration profiles and bioavailability of the drug. In the case of cancer indications, the nanoemulsion and nanoparticle form offers a higher potential of killing the cancer cells, as well as better treatment of cancer, osteoarthritis, and fibromyalgia, among others. With the constant demand for new and improved vaccines, nanoemulsion applications are expected to increase, globally, and drive the market.
Key Market Trends
Antibiotics is Expected to Register a Healthy CAGR Over the Forecast Period
Nanoemulsion formulations are becoming clinically useful as they can provide a substantial advantage over the conventional formulation of antibiotics. This is because the antibacterial activity of antibiotics can be enhanced significantly by dispensing them in a nanoparticle form. Nanoemulsions are used extensively in antibiotic drug deliveries and they have varied purposes. They can act as effective carriers for the bioactivation of antibiotics, helping its administration through various routes such as transdermal, topical, and oral delivery. There is a rising interest in the application of nanoemulsion in antimicrobial properties and effective anti-biofilm agents. This is expected to positively affect market development during the forecast period.
Rising antibiotic resistance has received increased attention from researchers and companies across the world. However, the rate of new antibiotics released in the market for therapeutic treatment against emerging "superbugs" has been low. A large number of research articles have been published in the Asian Journal of Pharmaceutical Education and Research, 2017 that study nanoemulsions and their antibacterial properties, such as stability and antibacterial properties of erythromycin oil-in-water nanoemulsion against Pseudomonas Aeruginosa,
Staphylococcus Aureus, and Streptococcus Pneumonia. With increasing applications in a wide range of antibiotics for treating various diseases and the emergence of better treatment possibilities, the companies that invest in the antibiotics segment are steady. Thus, the success rate and adoption may further determine the growth of this market over the forecast period.
There are various modes for the administration of nanoemulsion based medicines. Oral and parenteral podes are quite popular although other methods (for example, through eye droplets) are also popular. Companies operating in the market collaborate for novel product development. For example, in May 2018, Ascendia Pharmaceuticals, a specialty pharmaceutical company announced a collaboration with KC Pharmaceuticals for the development of over-the-counter (OTC) sterile ophthalmic drop medicines. Initiatives such as these are likely to boost market growth and development.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the overall market during the forecast period, due to the presence of key players, high prevalence of chronic diseases in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the legalization of cannabis-based products are some of the drivers expected to increase the market growth. In this region, Canada is fast becoming a prominent player. The Canadian cannabis industry is one of the largest in the world. Nanoemulsions are being used by pharmaceutical drug manufacturers operating in this field. In June 2020, Emerald Health Therapeutics, Inc., launched a new nanoemulsion-based Fast Action Spray product line involving cannabis infused with nanoemulsion. The innovative formulation offers unique advantages over existing formats of cannabis consumption in terms of convenience and predictability of consumption.
In February 2020, Pressure BioSciences, Inc. a company based in Massachusetts, United States, announced the opening of its Ultra Shear Technology Demonstration Laboratory that can process CBD oil into high quality, water-soluble nanoemulsions. The UST Demo Lab is located in the Company's South Easton facility in Massachusetts. The UST Demo Lab will study ways to make hemp-derived cannabinoid oil effectively soluble in water and to optimize absorption and bioavailability when consumed or applied.
Innovative product development by major companies in this region are expected to have a positive effect on the nanoemulsion market.
The nanoemulsion market is moderately competitive and consists of a few major players and several small players. In terms of market share, the major players, namely, Ascendia Pharmaceuticals, Covaris Inc., Microfluidics (IDEX Corporation), Taiwan Liposome Company Ltd, and Allergan PLC, currently dominate the market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 High Stability and Chemical Properties for Efficient Drug Delivery
- 4.2.2 Increasing Burden of Chronic Diseases and Development of Vaccines
- 4.2.3 Rising Adoption of Targeted Therapeutics and Image-guided Therapies
- 4.3 Market Restraints
- 4.3.1 High Manufacturing Expenses and Technical Difficulties
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Application
- 5.1.1 Anesthetics
- 5.1.2 Antibiotics
- 5.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 5.1.4 Immunosuppressants
- 5.1.5 Steroids
- 5.1.6 Other Applications
- 5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Parenteral
- 5.2.3 Other Routes of Administration
- 5.3 Geography
- 5.3.1 North America
- 22.214.171.124 United States
- 126.96.36.199 Canada
- 188.8.131.52 Mexico
- 5.3.2 Europe
- 184.108.40.206 Germany
- 220.127.116.11 United Kingdom
- 18.104.22.168 France
- 22.214.171.124 Italy
- 126.96.36.199 Spain
- 188.8.131.52 Rest of Europe
- 5.3.3 Asia-Pacific
- 184.108.40.206 China
- 220.127.116.11 Japan
- 18.104.22.168 India
- 22.214.171.124 Australia
- 126.96.36.199 South Korea
- 188.8.131.52 Rest of Asia-Pacific
- 5.3.4 Rest of World
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Allergan PLC
- 6.1.2 Ascendia Pharmaceuticals
- 6.1.3 Covaris Inc.
- 6.1.4 Foamix Pharmaceuticals
- 6.1.5 Latitude Pharmaceuticals Inc.
- 6.1.6 Microfluidics (IDEX Corporation)
- 6.1.7 Mitsubishi Tanabe Pharma
- 6.1.8 Santen Pharmaceutical Co. Ltd
- 6.1.9 Taiwan Liposome Company Ltd
- 6.1.10 Owen Biosciences, Inc
- 6.1.11 Latitude Pharmaceuticals Inc.
- 6.1.12 BlueWillow Biologics, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS